



Feasibility and Safety of Laparoscopic Partial Splenectomy: A Systematic Review

Gangshan Liu¹ · Ying Fan¹

Published online: 14 February 2019
© Société Internationale de Chirurgie 2019

Abstract

Background Laparoscopic partial splenectomy (LPS) is a challenging procedure. The aim of this review was to evaluate its feasibility, safety, and potential benefits.

Methods We conducted a comprehensive review for the years 1995–2018 to retrieve all relevant articles.

Results A total of 44 studies with 252 patients undergoing LPS were reviewed. Six studies described combined operations. Ranges of operative time and estimated blood loss were 50–225 min and 0–1200 ml, respectively. There are eight patients need blood transfusion in 231 patients with available data. The conversion rate was 3.6% (9/252). Overall, 27 patients (10.7%;27/252) developed postoperative or intraoperative complications. Overall mortality was 0% (0/252). The length of postoperative stay (POS) varied (1–11 days). Among four comparative studies, one showed LPS could reduce POS than laparoscopic total splenectomy (LTS) (LTS 5.4 ± 1.8 days, LPS 4.2 ± 0.8 days, $p = 0.027$) and complications (pleural effusion (LTS 9/22, LPS 0/15, $p = 0.005$), splenic vein thrombosis (LTS 10/22, LPS 0/15, $p = 0.002$)). Another comparative study showed LPS may benefit emergency patients. However, one comparative study showed LPS was associated with more pain, longer time to oral intake, and longer POS in children with hereditary spherocytosis. The fourth comparative study showed robotic subtotal splenectomy was comparable to laparoscopy in terms of POS and complication. The main benefits were lower blood loss, vascular dissection time, and a better evaluation of splenic remnant volume.

Conclusions In early series of highly selected patients, LPS appears to be feasible and safe when performed by experienced laparoscopic surgeons.

Introduction

For decades, the unnecessary roles of spleen have led surgeons to remove the total spleen without hesitation until a retrospective analysis of 2796 splenectomy cases

managed in the 1970s showed that septic infections developed in 119 patients (4.25%) and that 71 of these patients (60%) succumbed to their infections [1]. With the better understanding of the importance of the spleen as an important organ of immune system and of the long-term complications in terms of total splenectomy [2–4], more and more surgeons prefer to parenchyma-preserving surgical procedures. Partial splenectomy is a good method to prevent post-splenectomy infections by preservation of the immunologic role of the spleen [5, 6]. The first successful partial splenectomy through open approach was reported in 1980 by Morgenstern and Shapiro [7]. However, LPS is still a challenging procedure. One major difficulty when

✉ Ying Fan
m18940258876@163.com; coolingpine78@163.com

Gangshan Liu
lgs996635919@163.com

¹ Department of the Second General Surgery, Sheng Jing Hospital of China Medical University, No. 36, Sanhao Street, Heping District, Shenyang City, Liaoning Province, China

considering LPS is the risk of intraoperative and/or post-operative bleeding. Nevertheless, with the development of technology and understanding of the end-vascular distribution of intrasplenic vessels, LPS was possible. We knew later that the splenic artery branches in superior and inferior polar arteries, which further divide into several segmental intrasplenic end arteries [8, 9]. The first LPS procedure was performed in 1995 by Uranus et al. in pigs [10]. Poulin et al. [11] reported the first case of LPS for ruptured spleen in 1995. Today, LPS is being increasingly advocated and recommended, and even the first case of single-port LPS has been reported by Tae Ho Hong in 2010 [12]. The aim of this review was to evaluate the feasibility, safety, and potential benefits of LPS.

Materials and methods

Literature search strategies

A systematic search of the scientific literature was carried out using the PubMed, relevant online journals, and the Internet for the years 1995–2018 to obtain access to all publications involving LPS for humans. Searches were conducted restricted to English in language. To avoid duplication of data, articles from the same unit or hospital were included only once if data were being updated in a later publication. The search terms were “laparoscopic partial splenectomy,” “laparoscopic subtotal splenectomy,” “laparoscopic splenic surgery,” “Robotic partial splenectomy,” “Robot-assisted partial splenectomy,” “Robotic subtotal splenectomy.” The search strategy applied to PubMed is listed as below: (((laparoscopic

partial splenectomy) OR laparoscopic subtotal splenectomy) OR Robotic partial splenectomy) OR Robot-assisted partial splenectomy) OR Robotic subtotal splenectomy. All available major publications from the past 24 years were considered.


Inclusion criteria

Articles were selected if the abstract contained data of patients who underwent LPS for splenic diseases in the form of case reports, controlled or comparative studies, and articles about summary of experience. Conference abstracts were included if they contained relevant data. The reference lists of these articles were also reviewed to find additional candidate studies. In the case of duplicate publications, the latest and most complete study was included. Letter articles or review articles were excluded from this study. Data extracted for this study were taken from the published reports; authors were not contacted to obtain additional information. All articles selected for review of full text were distributed to two reviewers (Y.F. and G.L), who independently decided on inclusion/exclusion and independently abstracted the study data. Any discrepancies in agreement were resolved by consensus. The flowchart of this selection process is summarized in Fig. 1. IRB approval was not needed for this paper.

Results

Using the search strategy mentioned above, a total of 60 potentially relevant citations were found. We excluded two irrelevant articles (one letter article and one only surgical

Fig. 1 Flowchart of the selection process for studies included in the systematic review



technique description) and two non-English articles by review of titles and abstracts. Forty-nine publications were selected for review of full text and three duplicate publications, one article undergone LPS for pigs not human, and eight articles that we could not get detailed data were excluded from our review. Forty-four [5, 6, 11–52] with a total of 252 patients undergoing LPS or LSS met the criteria for analysis. These included four case-matched comparative studies. There were no RCTs or meta-analyses.

Indications and procedures of LPS

Indications for LPS varied in these series (Table 1). The most common indications in these series were splenic cystic lesions ($n = 84$) [5, 6, 12–30, 51, 52], followed by splenic hematological diseases ($n = 70$) [5, 6, 21, 24, 31, 33–35], non-cystic intraparenchymal lesions ($n = 59$) [5, 6, 20–24, 36–44, 50, 52], spleen rupture ($n = 22$) [11, 45], splenomegaly of unknown origin ($n = 9$) [5], splenic abscess ($n = 3$) [23, 42, 49], severe splenic pain due to ischemia provoked by vascular obstruction of the spleen ($n = 2$) [47], and each for Gandy–Gamna bodies, Benign metaplasia, and undiagnosed splenic lesion [22, 48]. The most common surgical procedures performed in these series were four-trocar laparoscopic splenectomy ($n = 117$) [14, 16–18, 20, 22–24, 28, 30, 31, 35, 38, 39, 42, 43, 45, 47, 48, 50, 51], followed by three-trocar laparoscopic splenectomy ($n = 53$) [5, 15, 19, 21, 26, 27, 33], five-trocar laparoscopic splenectomy ($n = 47$) [11, 13, 31, 34, 41, 46, 49, 52], two-trocar laparoscopic splenectomy ($n = 4$) [39, 40], single-incision laparoscopic splenectomy ($n = 2$) [12–29], and hand-assisted laparoscopic partial splenectomy ($n = 1$) [36]. Six studies described combined operations including 16 cases of cholecystectomy [6, 31, 32, 34], case of esophagogastric devascularization [35], and one case of hepatic hydatid cyst excision [29].

Operative parameters (operative time, blood loss, blood transfusion, conversion, etc.)

Various operative parameters are summarized in Table 2. The range of operative times of LPS (including combination operation) procedure was 50–225 min ($n = 37$ studies) [5, 6, 11–14, 16–18, 20–26, 28, 29, 31–36, 38–46, 48–52]. The range of estimated blood loss (EBL) was 0–1200 ml ($n = 39$ studies) [6, 11–18, 20–26, 28–36, 38–46, 48–52]. There are eight patients need blood transfusion in 231 patients with available data (except Li et al. [45] with no available data which contained 21 patients diagnosed with splenic rupture). Among all 252 cases eligible in the current review, a total of five cases (1.98%) were converted to laparoscopic total splenectomy [20, 22, 33, 45], but one

was happened 2 years later after LPS [33]. Three cases (1.19%) were converted to open partial splenectomy [5, 22], and 1 case (0.40%) was converted to open total splenectomy 11 months later after LPS [34]. Main reasons of conversion to LTS in these cases were as follows: subsequent unstable vital sign during LPS in two cases [45], hemorrhage in the splenic artery as a result of failure to fire the stapler in one case [20], fresh-frozen tissue examination could not overrule malignancy in one case [22], one case developed splenic regrowth accompanied by worsening hemolysis and anemia 2 years later [33]. The reasons of conversion to open partial splenectomy were bleeding [5] or pneumothorax [22] resulting from dissection of inflammatory adhesions between the spleen and the diaphragm. One patient required open splenic remnant removal 11 months after initial surgery due to persistent mild hemolytic anemia and adhesion of the splenic remnant [34]. There was one intraoperative complication (a small bowel tear) during spleen extraction, and then, the portion of small bowel was resected with a functional end-to-end stapled anastomosis.

Resected specimen

For 60 children with hereditary spherocytosis [6, 31–34], they underwent laparoscopic subtotal splenectomy. The remnant spleen size was 10–30% [32–34], with upper pole preserved in 40 patients [6, 31–34] and lower pole preserved in 20 patients [6, 34].

Perioperative mortality

None perioperative death was observed among all studies.

Morbidity, reoperation and hospital stay

Postoperative morbidities varied across studies (0–33.3%). Overall, 27 patients (10.71%; 27/252) developed complications. Postoperative fluid collection occurred in 15 cases [5, 6, 20, 22, 28, 34, 35, 45]. Among them, one patient suffered from intraperitoneal fluid collection requiring radiological drainage [22], one patient got left subphrenic fluid collection which could not be approached percutaneously and required a laparoscopic drainage [28], and others were treated conservatively. Postoperative wound infection occurred in two cases [33, 34] without special treatment. Postoperative portal vein thrombosis occurred in one case [20] and underwent laparoscopic total splenectomy. Postoperative pulmonary embolism occurred in one case [22] and required prolonged anticoagulation. Postoperative ileus occurred in one case [33] who was treated with nasogastric tube decompression and resolved after 3 days. Postoperative atelectasis occurred in two cases [23]

Table 1 Indications for LPS varied in these series

		Splenic hematological diseases				
Splenic cystic lesions		Secondary		Hereditary spherocytosis	Thrombocytopenia	Hemoglobinosis E
Primary		Traumatic				
Parasitic (hydatid cyst)		Non-parasitic				
Number of cases		71	7	68	1	1
References		[5, 6, 12–24, 27, 51, 52]	[22, 25, 26, 52]	[5, 6, 31–34]	[35]	[6]
Non-cystic intraparenchymal lesions						
Benign tumors						
Hemangiomas		Hemangiomas	Hemolymphangioma	Hamartomas	Lymphangioma	Malignant tumor
					Primary	Secondary
Number of cases		1	1	9	17	2
References		[6]	[41]	[5, 23, 39]	[20, 23, 24, 43, 52]	[39, 44]
Spleen rupture		Splenomegaly of unknown origin	Splenic abscess	Severe splenic pain (Due to ischemia provoked by vascular obstruction of the spleen)	Gandy–Gamma bodies	Benign metaplasia
Number of cases		9	3	2	1	1
References		[5]	[23, 46, 49]	[47]	[22]	[22]
						[48]
						Undiagnosed splenic lesion

Table 2 Perioperative parameters of laparoscopic partial splenectomy included studies

Author	No.	Disease	Size of disease (mm)	Combined operation	No. of port					Operating time(min)
					Five	Four	Three	Two	One	
Robert [13]	1	SEC	58 * 56 * 53	None	1	0	0	0	0	223
Khelif [14]	2	SC	70 * 65 * 60 80 * 60 * 60	None	0	2	0	0	0	90 180
Andrew [15]	1	SEC	100	None	0	0	1	0	0	NA
Jain[16]	1	SEC	60 * 60	None	0	1	0	0	0	190
Hong [12]	1	SC	100 * 80 * 70	None	0	0	0	0	1	145
N hua [17]	1	SEC	132 * 106 * 124	None	0	1	0	0	0	120
Lima [18]	5	SC	90 * 90 91 * 100 68 * 57 150 * 140 80 * 70	None	0	5	0	0	0	120 300 210 180 200
Garza-Serna [19]	1	SC	50	None	0	0	1	0	0	NA
Uranues [5]	38	SMG (n = 9) SC (n = 16) Re-SC (n = 4) Ham (n = 6) HS (n = 1) SM (n = 2) HS (n = 6) HE (n = 1) He (n = 1) He (n = 1) SEC (n = 2)	NA	None	0	0	38	0	0	74 (69–87) 102 (65–130) 120 (105–148) 104 (75–125) 102 95 (90–100)
Hery [6]	11	HS (n = 6) HE (n = 1) He (n = 1) He (n = 1) SEC (n = 2)	NA	Cholecystectomy in two cases	NA	NA	NA	NA	NA	NA
Wang [20]	11	SC (n = 6) Ly (n = 3) He (n = 2)	53 (40–95)	None	0	11	0	0	0	148 (110–200)
Dudi-Venkaa [21]	2	SC (n = 1) He (n = 1)	100 * 90 * 80 50 * 50 * 40	None	0	0	2	0	0	100; 80

Table 2 continued

Author	No.	Disease	Size of disease (mm)	Combined operation	No. of port					Operating time(min)
					Five	Four	Three	Two	One	
de la Villeon[22]	12	SC (n = 6) He (n = 2) GG (n = 1) BM (n = 1) SSC (n = 2)	70 (40–120)	None	0	12	0	0	0	120 (80–180)
Lee [23]	15	SC (n = 4) He (n = 3) Ly (n = 4) SA (n = 1) Ham (n = 2)	72 ± 32	None	0	15	0	0	0	168.8 ± 46.8
Cai [24]	18	SM (n = 1) SC (n = 12) He (n = 2) Ly (n = 4) SSC (n = 1) SSC (n = 1) SC (n = 1) SHC (n = 4) SHC (n = 1)	>50	None	0	18	0	0	0	54.3 ± 16.6
Corcione [25]	1	SSC (n = 1)	NA	None	NA	NA	NA	NA	NA	70
Smith [26]	1	SSC (n = 1)	100	None	0	0	1	0	0	120
Limuro [27]	1	SC (n = 1)	140 * 150	None	0	0	1	0	0	NA
Vasilescu [28]	4	SHC (n = 4)	NA	None	0	4	0	0	0	120 ± 37
Chinnusamy [29]	1	SHC (n = 1)	63 * 76	Hepatic hydatid cyst excision	0	0	0	0	1	160
Quesada [30]	1	SHC (n = 1)	120 * 140 * 166	None	0	1	0	0	0	NA
Morinis [31]	9	HS (n = 9)	NA	Cholecystectomy in four cases	4	5	0	0	0	215.6 ± 20.6
Rescorla [32]	11	HS (n = 11)	NA	Cholecystectomy in one case	NA	NA	NA	NA	NA	NA
Slater [33]	9	HS (n = 9)	NA	None	0	1	8	0	0	146;135
Vasilescu [34]	32	HS (n = 32)	NA	Cholecystectomy in nine cases	22	10	0	0	0	95 (laparoscopic); 107.5 (robotic)
Vasilescu [35]	1	ITP (n = 1)	NA	Esophagogastric devascularization	0	1	0	0	0	160
Okano [36]	1	He	35 * 33	None	Hand-assisted	+3 pores				NA
Budzynski [37]	1	He	85 * 75 * 90	None	0	1	0	0	0	NA
Breitenstein [38]	1	He	10	None	0	1	0	0	0	170

Table 2 continued

Author	No.	Disease	Size of disease (mm)	Combined operation	No. of port					Operating time(min)
					Five	Four	Three	Two	One	
Patrzyk [39]	3	He (n = 1) PM (n = 1) Ham (n = 1)	NA	None	0	0	0	3	0	144 (110–187)
Benetatos [40]	1	He (n = 1)	55 * 36	None	0	0	0	1	0	50
Zhang [41]	1	Ly (n = 1)	157 * 85	None	1	0	0	0	0	105
Han [42]	6	He (n = 6)	NA	None	0	6	0	0	0	168 (100–225)
Wang [43]	1	Ly (n = 1)	15 * 10	None	0	1	0	0	0	170
Vega [44]	1	UPM (n = 1)	NA	None	NA	NA	NA	NA	NA	180
Li [45]	21	SR (n = 21)	NA	None	0	21	0	0	0	122.6 ± 18.7
Poulin [11]	1	SR (n = 1)	NA	None	1	0	0	0	0	150
De Greef[46]	1	SA (n = 1)	70 * 40 * 40	None	1	0	0	0	0	75
Petroianu [47]	2	SSP (n = 2)	NA	None	0	2	0	0	0	NA
Seshadri [48]	1	USL (n = 1)	30 * 20	None	0	1	0	0	0	200
De Pastena [49]	1	SA (n = 1)	9	None	1	0	0	0	0	210
Zheng [50]	1	He (n = 1)	33 * 21	None	0	1	0	0	0	100
Ramia [51]	1	SC (n = 1)	80	None	0	1	0	0	0	NA
Chen [52]	16	SC (n = 5) SSC (n = 3) He (n = 3) Ly (n = 5)	87 (50–170)	None	16	0	0	0	0	157 (110–195)

Table 2 continued

Author	EBL(ml)	Conversion (%)	Blood transfusion(%)	Extent of resection	Complication (%)	Postoperative stay (day)	Drainage yes/no (day)
Robert [13]	NA	0	0	0	0	NA	None
Khelif [14]	0	0	0	0	0	2	None
Andrew [15]	30	0	0	0	0	4	None
Jain[16]	Minimal	0	0	0	0	5	None
Hong [12]	Minimal	0	0	0	0	3	None
N hua [17]	Minimal	0	0	0	0	4	None
Lima [18]	NA	0	NA	Upper pole (n = 5)	0	3	1
						7	NA
						5	
						5	
						4	
						5	
Garza-Serna [19]	NA	0	0	Lower pole	0	2	None
Uranues [5]	NA	5.26 (n = 2) to OPS	7.89 (n = 3)	Upper pole (n = 18), Lower pole (n = 16), Subtotal (n = 3)	5.26 (n = 2)	5 (4–7)	NA
Hery [6]	Minimal	0	0	Subtotal (n = 11)	9.09 (n = 1)	7.7 (3–10)	NA
Wang [20]	189 (100–400)	9.09 (n = 1) to LTS	0	Upper pole (n = 6), Lower pole (n = 4), Subtotal (n = 1)	18.18 (n = 2)	5 (4–7)	Yes
Dudi-Venkaa [21]	250;100	0	0	Upper pole (n = 2)	0	4;4	None
de la Villeon[22]	90 (10–450)	16.67 (n = 2) to LTS	0	Upper pole (n = 10), Lower pole (n = 2)	16.67 (n = 2)	5 (4–7)	2
		OPS (n = 1); OPS (n = 1)					

Table 2 continued

Author	EBL(ml)	Conversion (%)	Blood transfusion(%)	Extent of resection	Complication (%)	Postoperative stay (day)	Drainage yes/no (day)
Lee [23]	422.6 ± 187.4	0	20 (n = 3)	Upper pole (n = 3), Lower pole (n = 12)	20 (n = 3)	4.2 ± 0.8	2.6 ± 1.1
Cai [24]	75.8 ± 33.5	0	0	Upper pole (n = 12), Lower pole (n = 6)	0	6.6 ± 3.2	Yes
Corcione [25]	NA	0	0	ULHS (n = 1)	0	NA	NA
Smith [26]	NA	0	0	LLHS (n = 1)	0	1	None
Limuro [27]	NA	0	0	Lower pole (n = 1)	0	NA	NA
Vasilescu [28]	Minimal	0	0	ULHS (n = 1) Subtotal (n = 3)	25 (n = 1)	5 ± 2	Yes
Chinnusamy [29]	NA	0	0	Lower pole (n = 1)	0	5	None
Quesada [30]	<200	0	0	Lower pole (n = 1)	0	3	NA
Morinis [31]	188.8 ± 159	0	11.11 (n = 1)	Preserved upper pole	0	6.3 ± 1.0	NA
Rescorla [32]	NA	0	0	Preserved upper pole	0	NA	NA
Slater [33]	Minimal	11.11 (n = 1)	11.11 (n = 1)	Preserved upper pole	33.33 (n = 3)	3.6 (1–6)	None
Vasilescu [34]	90 (laparoscopic group); 35 (robotic group)	3.125 (n = 1) to OS	0	Preserved upper pole (n = 7); Preserved lower pole (n = 25)	12.5 (n = 4)	4.45 (laparoscopic group); 4.2 (robotic group)	None
Vasilescu [35]	150	0	0	Preserved lower pole	0	5	None
Okano [36]	0	0	0	Lower pole (n = 1)	7	7	NA
Budzynski [37]	NA	0	0	Upper pole (n = 1)	0	NA	NA
Breitenstein [38]	<150	0	0	Lower pole (n = 1)	0	3	None
Patrzyk [39]	30 (20–40)	0	0	NA	0	5	NA

Table 2 continued

Author	EBL(ml)	Conversion (%)	Blood transfusion(%)	Extent of resection	Complication (%)	Postoperative stay (day)	Drainage yes/no (day)
Benetatos [40]	<20	0	0	Upper pole (n = 1)	0	2	None
Zhang [41]	80	0	0	Upper pole (n = 1)	0	NA	NA
Han [42]	383 (100–1200)	0	0	NA	0	7.8 (6–11)	5.3 (3–9)
Wang [43]	30	0	0	Upper pole (n = 1)	0	7	NA
Vega [44]	175	0	0	Upper pole (n = 1)	0	0	NA
Li [45]	174 ± 22	9.52 (n = 2) to LTS	221 ± 36 ml (auto); 125 ± 25 ml (allo)	Lower pole (n = 9)	19.05 (n = 4)	5.2 ± 1.1	NA
Poulin [11]	<50	0	0	Upper pole (n = 12)	0	3	None
De Greef[46]	100	0	0	Upper pole (n = 1)	0	7	Yes
Petroianu [47]	NA	0	0	NA	0	2	None
Seshadri [48]	200	0	0	Lower pole (n = 1)	0	2	NA
De Pastena [49]	20	0	0	Upper pole (n = 1)	0	7	None
Zheng [50]	50	0	0	Upper pole (n = 1)	0	NA	2
Ramia [51]	130	0	0	Lower pole (n = 1)	0	1	None
Chen [52]	80–200	0	0	Lower pole (n = 2)	0	5–6	3–5
				ULHS			

ITP idiopathic thrombocytopenia purpura; *HS* hereditary spherocytosis; *SC* splenic cyst; *SHC* splenic hydatid cyst; *SEC* splenic epidermoid cyst; *Re-SC* recurrent splenic cyst; *SSC* secondary splenic cyst; *HE* hemoglobinosis E; *He* hemangiomas; *Ly* lymphangioma; *Ham* hamartoma; *Hae* hemangiomas; *SA* splenic abscess; *SMG* splenomegaly; *SM* secondary malignancy; *PM* primary malignancies; *UPM* unknown primary malignancies; *GG* Gandy–Gamma bodies; *BM* benign metaplasia; *SR* spleen rupture; *SSP* severe splenic pain *USL* undiagnosed splenic lesion; *CO* combined operation; *OT* operation time; *EBL* estimated blood loss; *CV* conversion; *PC* postoperative complications; *RO* reoperation; *POS* postoperative stay; *OS* open splenectomy; *OPS* open partial splenectomy; *LTS* laparoscopic total splenectomy; *ULHS* Upper laparoscopic hemisplenectomy; *LLHS* lower laparoscopic hemisplenectomy

without further treatment. Postoperative thrombocytosis occurred in one case [23] and required taking aspirin orally. Intraoperative small bowel tearing during spleen extraction occurred in one case [33], and the portion of small bowel was resected, and then, a functional end-to-end stapled anastomosis was fashioned. No bleeding complication occurred. In 35 studies with available data [5, 6, 11, 12, 14–21, 23–26, 28–31, 33–36, 38–40, 43, 44, 46–49, 51, 52], the average/median length of POS also varied from 1 to 11 days across reports. Notably, 14 studies [11, 14, 16, 17, 19, 25, 26, 30, 38, 40, 44, 47, 48, 51] reported less than or equal to 3 days of average/median POS in their series.

Comparison of short-term outcomes between LPS and LTS

There were only three reports [23, 31, 45], which compared outcomes between LPS and LTS.

Morinis et al. [31] compared nine patients with hereditary spherocytosis (HS) undergoing LPS with nine children undergoing LTS over the same period which showed that EBL was greater in the LPS group (188 + 53 vs. 67 + 17 mL; $P = 0.02$), but transfusion requirements were similar (1/9 vs. 0/9). The LPS group had higher morphine use (4.1 + 0.6 vs. 2.4 + 0.2 days; $P = .03$), greater time to oral intake (4.4 + 0.7 vs. 2.0 + 0.2 days; $P = .01$), and longer hospital stay (6.3 + 1.0 vs. 2.7 + 0.3 days; $P = .005$) than the LTS group. There was no significant difference between groups with respect to increase in hemoglobin level. No patient in the LPS group required completion splenectomy after a mean follow-up of 25 months. Groups were similar in sex, age, concomitant cholecystectomy, complication rate and preoperative hospitalizations, transfusions, and spleen size.

Lee et al. [23] compared 22 patients undergoing LTS and 15 patients undergoing LPS and reported that there were significant differences in postoperative complications such as pleural effusion (LTS 9/22 [40.9%], LPS 0/15 [0%], $p = 0.005$), splenic vein thrombosis (LTS 10/22 [45.5%], LPS 0/15 [0%], $p = 0.002$), and postoperative hospital stay (LTS 5.4 ± 1.8 days, LPS 4.2 ± 0.8 days, $p = 0.027$). There were no significant differences between the groups in terms of the operative time (LTS 151.5 ± 98.5 min, LPS 168.6 ± 46.8 min, $p = 0.483$), intraoperative blood loss (LTS 337.3 ± 188.4 ml, LPS 422.6 ± 187.4 ml, $p = 0.185$), and transfusion rate (LTS 3/22 [13.6%], LPS 3/15 [20.0%], $p = 0.606$) As their conclusion, LPS is a feasible, safe surgical procedure in patients with tumorous lesions of the spleen, and it represents an effective approach to reduce postoperative hospital stay and complications.

Li et al. [45] compared 21 patients diagnosed with splenic rupture who underwent LPS and 20 patients diagnosed with splenic rupture who underwent LTS and reported that the counts of platelet (LPS: $147 \pm 48 * 10^9$ vs. LS: $282 \pm 61 * 10^9$, $P = .031$) and leukocyte (LPS: $6.7 \pm 1.1 * 10^9$ vs. LS: $8.9 \pm 1.9 * 10^9$, $P = .017$) were significantly different. The operation time (LPS: 122.6 ± 17.2 min vs. LS: 110.5 ± 18.7 min, $P = .117$), intraoperative blood loss (LPS: 174 ± 22 mL vs. LS: 169 ± 29 mL, $P = .331$), autologous blood transfusion (LPS: 221 ± 36 mL vs. LS: 206 ± 27 mL, $P = .078$), allogeneic blood transfusion (LPS: 125 ± 25 mL vs. LS: 150 ± 30 mL, $P = .878$), and conversion to laparotomy (LPS: 0 vs. LS: 0, $P = 1.000$) were similar. So, they concluded that LPS may benefit emergency patients and does not increase perioperative risks.

Comparison of short-term outcomes between robotic subtotal splenectomy and LSS

Vasilescu et al. [34] compared 32 consecutive subtotal splenectomies by minimal approach in patients with hereditary spherocytosis (22 vs. 10 robotic laparoscopic subtotal splenectomies) and reported that a significant difference was found for the robotic approach regarding blood loss (90 (30–120) ml vs. 35 (15–85) ml, $p < 0.05$), vascular dissection duration (20 (15–30) min vs. 15 (15–20) min, $p < 0.05$), and splenic remnant size ($10.57 (6.37–17.14) \text{ cm}^3$ vs. $8.16 (6.12–11.81) \text{ cm}^3$, $P < 0.05$). They concluded that robotic subtotal splenectomy was comparable to laparoscopy in terms of hospital stay and complication. The main benefits were lower blood loss rate, vascular dissection time, and a better evaluation of the splenic remnant volume.

Discussion

Spleen is an important peripheral immune organ which has many functions such as regulating the circulating blood volume [53, 54], blood filtration, production of a variety of immunoglobulin and opsonins, and regulation of the endocrine system. The primary immunologic function of the spleen is to filter out virulent pathogens and antigens [2]. We all realized that total splenectomy could lead to several severe complications more easily than partial splenectomy such as pulmonary complications, overwhelming post-splenectomy infection (OPSI), and vascular derangements including thromboembolism and subsequent pulmonary hypertension [55]. According to the reports, the most serious complication caused by total splenectomy is OPSI, which can occur in up to 4.4% of the patients with splenectomy and carries a mortality risk of approximately

50–80% [56]. Singer et al. studied that partial splenectomy and using vaccines preoperatively and postoperatively were good ways to prevent OPSI [1] although Ziske et al. [57] reported one case of fatal OPSI occurred 13 years after partial splenectomy for trauma with conservation of about 20% functional splenic parenchyma. The present data indicate that OPSI after partial splenectomy was greatly reduced.

The main technical difficulty for LPS is the risk of intraoperative and/or postoperative bleeding. Difficulties to control bleeding caused by the spleen are mainly related to the specific vascular anatomy. As we know later, the splenic artery is often divided into two or three groups of branches, and in some patients, the number of segments even ranges from three to seven [58]. Therefore, intraoperative ligation of the terminal divisions of the splenic vessels can lead to an ischemic demarcation zone clearly on the spleen surface. This makes the splenic parenchyma resection with less blood loss possible.

The most common indication in this review is splenic cysts. Laparoscopic cyst decapsulation is a safe and feasible option for superficial cysts in some published reports [59]; however, some studies have noted that there was a high recurrence rate of 64% over a mean follow-up of 12 months [60]. Uranues et al. [5] reported that the recurrence developed within a few months after deroofting, and the patients complained more severe symptoms than those they had experienced preoperatively. But for secondary cysts, Mertens et al. [61] concluded that laparoscopic deroofting should be reserved. However, there were five patients with secondary cysts who underwent LPS with well results in the literature 2,22 and 26. The secondary common indications for LPS in this review were splenic hematological diseases. Among them, hereditary spherocytosis was a major indication. But for LPS in this kind of patients, careful consideration on splenic volume remnant was very important. Bader-Meunier et al. demonstrated that leaving 25% of spleen with adequate perfusion was sufficient to preserve splenic function [62]. Growing evidence supports that preservation of 25–30% of the splenic parenchyma allows an appropriate immunologic response to antigen stimulus [5, 63, 64]. So LPS is also a challenging procedure that may be affected by an inappropriate evaluation of the splenic remnant.

According to series article review, the attitude regarding accessory spleens changed during the years. In 2006, Dutta et al. [65] reported that the small accessory spleen was found and left in situ because the overall intent was to leave some spleen intact to retain immunologic function, and its size did not add significantly to the remnant volume. In 2008, Hery et al. [6] reported one patient had an accessory spleen, which was removed during the LPS procedure. In 2012, Vasilescu [34] reported four patients

detected with accessory spleens. For the first case, as their experience, they preserved the accessory spleen; afterward, for the last three patients, they choose to remove them to better assess the splenic remnant volume. There are no comparative studies about whether accessory spleen should be removed or not in partial splenectomy.

There are three comparative studies in this review between LPS and LTS. In 2008, Morinis et al. [31] reported that EBL was greater in the LPS group, but transfusion requirements were similar. LPS group had higher morphine use, greater time to oral intake, and longer POS than the LTS group. But these disadvantages may be balanced by retained splenic immune function, and further studies were required to assess long-term splenic function in these patients. So, in 2015, Lee et al. [23] reported that it represents an effective approach to reduce POS and complications for LPS. And there were no significant differences between the groups in terms of the operative time, intraoperative blood loss, and transfusion rate. As their conclusion, LPS was a feasible, safe surgical procedure in patients with tumorous lesions of the spleen. In 2017, Li et al. [45] compared patients diagnosed with splenic rupture and reported that the counts of platelet and leukocyte were less in LPS than LTS with significant difference. And the operation time, intraoperative blood loss, autologous blood transfusion, allogeneic blood transfusion, and conversion to laparotomy were similar. So, they concluded that LPS may benefit emergency patients and does not increase perioperative risks.

In conclusion, there are potential benefits associated with LPS over LTS, and in early series of highly selected patients, LPS appears to be feasible and safe when performed by experienced laparoscopic surgeons. However, there are no future multicenter RCTs or meta-analysis about the comparison between LPS and LTS. So, as a challenging operation, publication bias is a factor that should be considered before we can draw an objective conclusion.

Acknowledgement Gangshan Liu contributed to literature research and manuscript preparation. Ying Fan contributed to literature research and approved the final version of manuscript.

Compliance with ethical standards

Conflicts of interest Dr. Liu and Dr. Fan have no conflicts of interest or financial ties to disclose. Informed consent was obtained from all individual participants included in this review.

References

1. Singer DB (1973) Postsplenectomysepsis. In: Anonymous: Perspectives in pediatric pathology, 1edn Year Book Medical Publishers, Chicago, pp 285–311

2. Wolf HM, Eibl MM, Georgi E et al (1999) Long-term decrease of CD4⁺CD45RA⁺T cells and impaired primary immune response after post-traumatic splenectomy. *Br J Haematol* 107:55–68
3. Hansen K, Singer DB (2001) Asplenic-hyposplenic overwhelming sepsis: postsplenectomy sepsis revisited. *Pediatr Dev Pathol* 4:105–121
4. Tracy ET, Haas KM, Gentry T, Danko M, Roberts JL, Kurtzberg J, Rice HE (2011) Partial splenectomy but not total splenectomy preserves immunoglobulin M memory B cells in mice. *J Pediatr Surg* 46:1706–1710
5. Uranues S, Grossman D, Ludwig L et al (2007) Laparoscopic partial splenectomy. *Surg Endosc* 21:57–60
6. Hery G, Becmeur F, Mefat L et al (2008) Laparoscopic partial splenectomy: indications and results of a multicenter retrospective study. *Surg Endosc* 22:45–49
7. Ikeda M, Sekimoto M, Takiguchi S et al (2007) Total splenic vein thrombosis after laparoscopic splenectomy: a possible candidate for treatment. *Am J Surg* 193:21–25
8. De Schepper AM, Vanhoenacker F, de Beeck BO et al (2005) Vascular pathology of the spleen, part I. *Abdom Imaging* 30:96–104
9. Madoff DC, Denys A, Wallace MJ et al (2005) Splenic arterial interventions: anatomy, indications, technical considerations, and potential complications. *Radiographics* 25(Suppl 1):S191–S211
10. Uranüs S, Pfeifer J, Schauer C et al (1995) Laparoscopic partial splenic resection. *Surg Laparosc Endosc* 5:133–136
11. Poulin EC, Thibault C, DesCôteaux JG et al (1995) Partial laparoscopic splenectomy for trauma: technique and case report. *Surg Laparosc Endosc* 5:306–310
12. Hong TH, Lee SK, You YK et al (2010) Single-port laparoscopic partial splenectomy: a case report. *Surg Laparosc Endosc Percutan Tech* 20:e164–e166
13. Robert L, Soares JR et al (1998) Laparoscopic complete excision of a splenic epidermoid cyst. *J Laparosc Adv Surg Tech* 8:237–240
14. Khelif K, Maassarani F, Dassonville M et al (2006) Laparoscopic partial splenectomy using radiofrequency ablation for nonparasitic splenic cysts in two children. *J Laparosc Adv Surg Tech* 16:414–417
15. Gumbs AA, Bouhanna P, Bar-Zakai B et al (2008) Laparoscopic partial splenectomy using radiofrequency ablation. *J Laparosc Adv Surg Tech* 18:611–613
16. Jain P, Parelkar S, Shah H et al (2008) Laparoscopic partial splenectomy for splenic epidermoid cyst. *J Laparosc Adv Surg Tech* 18:899–902
17. Hua F, Zhang D, Xin Z et al (2011) Laparoscopic partial splenectomy for large splenic epidermoid cyst. *Chin Med J* 124:1751–1753
18. Lima M, Reinberg O, Ruggeri G et al (2013) 3D virtual rendering before laparoscopic partial splenectomy in children. *J Pediatr Surg* 48:1784–1788
19. Garza-Serna U, Ovalle-Chao C, Martinez D et al (2017) Laparoscopic partial splenectomy for congenital splenic cyst in a pediatric patient: case report and review of literature. *Int J Surg Case Rep* 33:44–47
20. Wang X, Wang M, Zhang H et al (2014) Laparoscopic partial splenectomy is safe and effective in patients with focal benign splenic lesion. *Surg Endosc* 28:3273–3278
21. Dudi-Venkata NN, Houli N, Weinberg L et al (2014) Laparoscopic partial splenectomy performed by monopolar saline-cooled radiofrequency coagulation. *J Laparosc Adv Surg Tech* 24:502–505
22. de la Villeon B, Zarzavadjian Le Bian A, Vuarnesson H et al (2015) Laparoscopic partial splenectomy: a technical tip. *Surg Endosc* 29:94–99
23. Lee SH, Lee JS, Yoon YC et al (2015) Role of laparoscopic partial splenectomy for tumorous lesions of the spleen. *J Gastrointest Surg* 19:1052–1058
24. Cai HH, An Y, Wu D et al (2016) Laparoscopic partial splenectomy: a preferred method for select patients. *J Laparosc Adv Surg Tech* 00:1–6
25. Corcione F, Cuccurullo D, Caiazzo P et al (2003) Laparoscopic partial splenectomy for a splenic pseudocyst. *Surg Endosc* 17:1850
26. Smith ST, Scoot DJ, Burdick JS et al (2001) Laparoscopic marsupialization and hemisplenectomy for splenic cysts. *J Laparosc Adv Surg Tech* 11:243–249
27. Jimuro Y, Okada T, Sueoka H et al (2013) Laparoscopic management of giant splenic true cyst with partial splenectomy: a case report. *Asian J Endosc Surg* 6:226–230
28. Vasilescu C, Tudor S, Popa M et al (2010) Robotic partial splenectomy for hydatid cyst of the spleen. *Langenbecks Arch Surg* 395:1169–1174
29. Chinnusamy P, Ahluwalia JS, Palanisamy S et al (2013) Single incision multi-trocar hepatic cyst with partial splenectomy. *J Minim Access Surg* 9(2):91–94
30. Quesada R, Poves M, Iglesias E Berjano et al (2016) Laparoscopic partial splenectomy for giant cyst using a radiofrequency-assisted device: a case report. *Surg Case Rep* 2:82
31. Morinis J, Dutta S, Blanchette V et al (2008) Laparoscopic partial vs total splenectomy in children with hereditary spherocytosis. *J Pediatr Surg* 43:1649–1652
32. Rescorla FJ, West KW, Engum SA et al (2007) Laparoscopic splenic procedures in children: experience in 231 children. *Ann Surg* 246:683–687
33. Slater BJ, Chan FP, Davis K et al (2010) Institutional experience with laparoscopic partial splenectomy for hereditary spherocytosis. *J Pediatr Surg* 45:1682–1686
34. Vasilescu C, Stanciulea O, Tudor S (2012) Laparoscopic versus robotic subtotal splenectomy in hereditary spherocytosis. Potential advantages and limits of an expensive approach. *Surg Endosc* 26:2802–2809
35. Vasilescu C, Stanciulea O, Popa M et al (2008) Subtotal laparoscopic splenectomy and esophagogastric devascularization for the thrombocytopenia because of portal cavernoma—case report. *J Pediatr Surg* 43:1373–1375
36. Okano K, Kakinoki K, Suto H et al (2011) Hand-assisted laparoscopic partial splenectomy using an endopath monopolar sealer. *Surg Laparosc Endosc Percutan Tech* 21:e291–e294
37. Budzyński A, Demczuk S, Kumięga B et al (2011) Sclerosing angiomatoid nodular transformation of the spleen treated by laparoscopic partial splenectomy. *Videosurg Other Miniinvasive Tech* 6(4):249–255
38. Breitenstein S, Scholz T, Schäfer M et al (2006) Laparoscopic partial splenectomy. *J Am Coll Surg* 204:179–181
39. Patrzyk M, Glitsch A, Hoene A et al (2011) Laparoscopic partial splenectomy using a detachable clamp with and without partial splenic embolisation. *Langenbecks Arch Surg* 396:397–402
40. Benetatos N, Filobos R, Ammor B (2011) Laparoscopic partial splenectomy for littoral cell angioma. *J Surg Case Rep* 7:4
41. Zhang Y, Chen XM, Sun DL et al (2014) Treatment of hemolymphangioma of the spleen by laparoscopic partial splenectomy: a case report. *World J Surg Oncol* 12:60. <https://doi.org/10.1186/1477-7819-12-60>
42. Han XL, Zhao YP, Chen G et al (2015) Laparoscopic partial splenectomy for splenic hemangioma: experience of a single center in six cases. *Chin Med J* 128:694–697
43. Wang WD, Lin J, Wu ZQ et al (2015) Partial splenectomy using a laparoscopic bipolar radiofrequency device: a case report. *World J Gastroenterol* 21(11):3420–3424

44. Vega EA, Yamashita S, Shin CY et al (2017) Laparoscopic partial splenectomy for unknown primary cancer: a stepwise approach. *Ann Surg Oncol* 24:1134
45. Li H, Wei Y, Peng B et al (2017) Feasibility and safety of emergency laparoscopic partial splenectomy. *Medicine* 96:16
46. De Greef E et al (2008) Partial laparoscopic splenectomy for splenic abscess because of Salmonella infection: a case report. *J Pediatr Surg* 43(5):E35–E38
47. Petroianu A, Cabezas-Andrade MA, Neto RB (2008) Laparoscopic subtotal splenectomy. *Surg Laparosc Endosc Percutan Tech* 18:94–97
48. Seshadri PA, Poulin EC, Mamazza J et al (2000) Technique for laparoscopic partial splenectomy. *Surg Laparosc Endosc Percutan Tech* 10:106–109
49. De Pastena M, Nikamp MW et al (2018) Laparoscopic hemi-splenectomy. *Surg Today* 48:735–738
50. Zheng L, Deng C, Li J et al (2018) Treatment of hemangioma of the spleen by preoperative partial splenic embolization plus laparoscopic partial splenectomy: a case report. *Medicine* 97:17
51. Ramia JM, de la Plaza Llamas R, López-Marcano AJ et al (2017) Laparoscopic partial splenectomy for a splenic epidermoid cyst. *Cir Esp* 95:613–615
52. Chen J, Shian Y, Longtang X (2018) Laparoscopic partial splenectomy: a safe and feasible treatment for splenic benign lesions. *Surg Laparosc Endosc Percutan Tech* 28:287–290
53. Tiron A, Vasilescu C (2008) Role of the spleen in immunity. Immunologic consequences of splenectomy. *Chirurgia (Bucur)* 103:255–263
54. Vasilescu C, Stanciulea O, Tudor S et al (2006) Laparoscopic subtotal splenectomy in hereditary spherocytosis: to preserve the upper or the lower pole of the spleen? *Surg Endosc* 20:748–752
55. Schilling RF (1997) Spherocytosis, splenectomy, strokes and heart attacks. *Lancet* 350:1677
56. Mouttalib S, Rice HE, Snyder D et al (2012) Evaluation of partial and total splenectomy in children with sickle cell disease using an Internet-based registry. *Pediatr Blood Cancer* 59:100–104
57. Ziske CG, Muller T (2002) Partial splenectomy: uses of error. *Lancet* 359:1144
58. Redmond HP, Redmond JM, Rooney BP et al (1989) Surgical anatomy of the human spleen. *Br J Surg* 76:198–201
59. Mackenzie RK, Youngson GG, Mahomed AA (2004) Laparoscopic decapsulation of congenital splenic cysts: a step forward in splenic preservation. *J Pediatr Surg* 39:88–90
60. Schier F, Waag KL, Ure B (2007) Laparoscopic unroofing of splenic cysts results in a high rate of recurrences. *J Pediatr Surg* 42:1860–1863
61. Mertens J, Penninckx F, DeWever I et al (2007) Long-term outcome after surgical treatment of nonparasitic splenic cysts. *Surg Endosc* 21:206–208
62. Bader-Meunier B, Gauthier F, Archambaud F et al (2001) Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. *Blood* 97:399–403
63. Van Wyck DB, Witte MH, Witte CL et al (1980) Critical splenic mass for survival from experimental pneumococemia. *J Surg Res* 28:14–17
64. Szczepanik AB, Meissner AJ (2009) Partial splenectomy in the management of nonparasitic splenic cysts. *World J Surg* 33:852–856. <https://doi.org/10.1007/s00268-008-9868-2>
65. Dutta S, Price VE, Blanchette V et al (2006) A laparoscopic approach to partial splenectomy for children with hereditary spherocytosis. *Surg Endosc* 20:1719–1724

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.